Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients

Keyphrases

• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 100%
• Haematopoietic Stem Cell Transplant Recipients 100%
• Dyslipidemia 100%
• Graft-versus-host Disease (GvHD) 66%
• Cardiovascular Disease 33%
• Hematopoietic Stem Cell Transplantation 33%
• Drug Interactions 33%
• Triglyceride Level 33%
• Survival Rate 33%
• Long-term Complications 33%
• Lipid-lowering Therapy 33%
• 3-hydroxy-3-methylglutaryl-coenzyme A 33%
• Adverse Effect Profile 33%
• Antihyperlipidemic 33%
• American Heart Association Guidelines 33%
• Relative Efficacy 33%
• Reductase Inhibitors 33%
• Cholesterol Levels 33%

Medicine and Dentistry

• Hematopoietic Stem Cell Transplantation 100%
• Dyslipidemia 100%
• Hyperlipidemia 66%
• Allogeneic Hematopoietic Stem Cell Transplantation 66%
• Graft Versus Host Reaction 66%
• Cardiovascular System 33%
• Drug Therapy 33%
• Clinician 33%
• Drug Interaction 33%
• Cardiovascular Disease 33%
• Adverse Event 33%
• Triacylglycerol 33%
• Survival Rate 33%
• Oxidoreductase 33%
• HMG-CoA 33%